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Aim: To study the effects of Paclitaxel (Ptx), γ-irradiation (IR) and their combination on the growth of xenografted tumors de-
rived from undifferentiated thyroid cancer cells. Materials and Methods: Experiments were performed in nude mice with tumors 
developing from implanted undifferentiated thyroid carcinoma cells (FRO). Animals were treated with Ptx i.p. and exposed locally 
to a single dose of 5 Gy of IR. Apoptosis in situ was detected using ApopTag Peroxidase Kit. Results: In the in vivo experiments, 
IR significantly inhibited but did not abrogate tumor growth. Ptx effect was stronger, and the combination therapy with Ptx and 
IR led to the decrease of tumor volume to 0-0.3% of the control (P < 0.01). The systemic administration of Ptx to the animals with 
advanced tumors resulted in a profound tumor growth suppression and in apoptosis in tumor tissues in time-dependent manner. 
Conclusion: The combination of Ptx and IR is a promising strategy for further preclinical and clinical trials aimed at the develop-
ment of new therapeutic approaches to the treatment of undifferentiated thyroid cancer.
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Paclitaxel (Ptx) has been successfully used to treat 
different types of human cancers [1]. Among those, 
the possibility of its application in one of the most ag-
gressive human tumors, anaplastic thyroid cancer 
(ATC), both as a monotherapy and in a combination 
with other anti-tumor agents was demonstrated [2–5]. 
Since Ptx mainly affects the microtubules thus block-
ing cell division, usage of additional agents that would 
damage DNA in tumor cells to cause genotoxic stress 
is a plausible modality. One of the agents widely used 
in combination with chemotherapy, is ionizing radiation 
(IR). It is known that Ptx enhances tumor cell radio-
sensitivity [6–9], possibly due to cell cycle arrest 
at G2/M phase in which the cells are considered 
to be more sensitive to radiation [8, 10]. The data 
obtained in our in vitro experiments showed that ion-
izing radiation significantly enhances proapoptotic 
effect of Ptx in anaplastic cancer cells [11]. The focus 
of this study was to elucidate the combined effect 
of low doses of Ptx and radiation on the in vivo growth 
of xenograft tumors developing from human undif-
ferentiated thyroid carcinoma cells implanted in im-
munocompromised mice. 
MATERIALS AND METHODS
Nude mouse xenograft model. Animal experi-
ments described in this study were conducted in ac-
cordance with the principles and procedures outlined 
in the Guide for the Care and Use of Laboratory Animals 
of the Biomedical Research Center, Center for Frontier 
Life Science (Nagasaki University, Nagasaki, Japan). 
Human follicular undifferentiated carcinoma cells FRO 
were initially provided by J. A. Fagin (University of Cin-
cinnati College of Medicine, Cincinnati, OH). Cells 
were grown in RPMI 1640 supplemented with 5% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (all 
reagents from Invitrogen Life Technologies, Paisley, 
UK) in a 5 % CO2 humidified atmosphere at 37 0C. FRO 
cells (5 x 106 cells per animal) resuspended in RPMI 
1640 were injected s.c. into both flanks of 8-week–old 
female BALB/c nu/nu mice (Charles River Japan, To-
kyo), 9 animals per group. Tumor sizes were measured 
each alternate day with calipers, and tumor volumes 
were calculated according to the formula a2 x b x 0.4, 
where a is the smallest tumor diameter and b is the 
diameter perpendicular to a. Treatment with Ptx and 
γ-irradiation started after the tumor size approached 
100 mm3. Ptx (10 mg/kg/day) diluted in Cremophor 
EL (Sigma, USA), ethanol and phosphate-buffered 
saline (PBS, pH 7.4) (1:1:1 v/v/v/) was injected in-
traperitoneally (i.p.) daily for 7 days. Animals from 
the control group received vehicle injections. For the 
exposure to γ-irradiation, anesthetized animals were 
fixed in stalls, and the tumors were locally exposed 
to a single dose of 5 Gy (Pony PS-3100SB, radiation 
source 137Cs, 0.662 MeV, 1 Gy/min) 4 days after Ptx 
treatment had started. Tumor size was monitored for 
four more weeks during which the body weight, feeding 
behavior, and motor activity of each animal were used 
as indicators of general health.
To determine the effect of low doses of Ptx on ad-
vanced tumors, animals were treated with i.p. Ptx 
injections at a dose of 2.5 mg/kg/day daily for 7 days. 
Tumor size was measured for 18 consecutive days.
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Histological estimation of apoptosis in the 
tumors. Needle biopsies of tumor tissues were fixed 
in 10% neutral-buffered formalin, and embedded 
in paraffin. Apoptotic cells were detected in 5-µm sec-
tions with an ApopTag Peroxidase Kit (Intergen Co., 
Burlington, MA). Positively stained cells were counted 
in four fields (x100) for each specimen, and the apop-
totic index was determined as the ratio of apoptotic 
cell number to total cell number.
Statistical analysis. All data were expressed 
as a mean ± SD. Differences between groups were ex-
amined for statistical significance using Kruskal—Wallis 
test (nonparametric ANOVA), Mann — Whitney test and 
one-way analysis of variance (ANOVA). P < 0.05 was 
considered indicating statistical significance.
RESULTS AND DISCUSSION
Treatment of anaplastic thyroid cancer cells in vitro 
with IR does not abrogate cell growth although moder-
ate doses (1–2 Gy) can rather effectively induce apop-
tosis and transient growth arrest [11, 12]. At first, this 
effect of IR was confirmed in the in vivo experiments 
(Fig. 1, a). FRO cells transplanted into mouse flanks 
quickly formed tumors. Twenty days after implantation, 
tumor size exceeded 1000% of the initial (100 mm3) 
in the control animals. In line with the in vivo experi-
ments, IR significantly (P < 0.05) reduced tumor size 
but did not prevent tumor growth. Treatment with Ptx 
was more effective (P < 0.05 as compared to irradi-
ated group). From the 11th day after the beginning 
of Ptx treatment, we observed a highly significant 
reduction of tumor volume as compared to both the 
control and to the initial volume. At 20–29 days tumor 
volume was 0.8–1% of control. The combined treat-
ment with radiation and Ptx showed the enhanced 
therapeutic effect (P < 0.05 as compared to the ir-
radiated animals). Seven days after the beginning 
of treatment, tumor size was significantly decreased; 
after 20–29 days it was 0.3% of the control (P < 0.01), 
and in two animals the tumors completely regressed. 
The combination of irradiation and Ptx was slightly 
more effective than Ptx alone, but the difference was 
insignificant. In in vitro experiments the additive effect 
of both agents regarding caspase-3 activation and 
PARP cleavage was observed [11].
Next, after finishing this experiment, the control 
group was split into 1 control and 8 experimental 
animals which were subjected to the treatment with 
4 times lower doses of Ptx (2.5 mg/kg/day). Fig. 
1 b shows that the tumor in the control animal con-
tinued to grow up to 1700 mm3 during further 18 days 
whereas those in the animals receiving Ptx were evi-
dently decreased. This observation indicates an ef-
ficiency of rather low doses of Ptx even in advanced 
tumors. 
Examination of the extent of apoptosis in tumor tis-
sues in situ in the advanced tumor group showed that 
after 11 days of treatment, Ptx effectively induced cell 
death, the intensity of which increased over the next 
18 days (Fig. 2).
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Fig. 1. Effect of IR and Ptx on the growth of tumor xenografts 
in vivo. (a) Effect of IR and Ptx as of monoagents and in combina-
tion. Ptx was injected i.p. at a dose of 10 mg/kg/day for 7 days. For 
IR-monotherapy and combination therapy, animals were exposed 
to a single dose of 5 Gy, 4 days after Ptx treatment had started. 
Data are presented as mean ± SD of 9 tumors. *P < 0.05 vs. con-
trol group (Mann — Whitney test); + P < 0.05 vs. irradiated group 
(Kruskal — Wallis test). (b) Effect of low doses of Ptx on advanced 
tumors. Animals were treated with Ptx i.p. injections at a dose 
of 2.5 mg/kg/day for 7 days. Data are presented as mean ± SD, 
n = 1 for the control group, n = 8 for the treatment group. *P < 
0.05 vs. n = 9 at day 0 (Kruskal — Wallis test) 
Despite the combined effect of Ptx and radiation 
in various tumors have been under investigation for 
a long time, the mechanism of radiosensitization is not 
fully understood. It is known that exposure to IR acti-
vates a complex system of sensors, mediators, signal 
transducers, and effectors. The latter two categories 
include checkpoint kinases, CHK1 and CHK2 (trans-
ducers), and p53 and Cdc25A-C (effectors) [13]. 
Their activities undergo changes under the action 
of both agents. The response of tumor cells to Ptx 
does not necessarily require the intact p53 and related 
signaling mechanisms [14 for rev.] as demonstrated, 
in particular, by its high cytotoxicity in ARO cells (ini-
tially assumed to be anaplastic thyroid carcinoma cell 
line but recently reclassified into colon carcinoma) 
with inactive TP53 [2]. In this study, the potentiation 
of cytotoxic effect of the combination therapy (Ptx 
and radiation) in tumors originating from FRO cells 
with wild-type p53 may perhaps be attributed in part 
to the activation of p53-dependent signaling pathways. 
In this case, the augmentation of apoptosis most likely 
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dominates over the mechanisms responsible for cell 
recovery and senescence.
Our in vivo data clearly show that treatment of ana-
plastic thyroid carcinoma with Ptx induces apoptosis 
in tumor tissue. Also, the use of moderate (1–5 Gy) 
doses of IR may be helpful for enhancement of Ptx 
effect on undifferentiated thyroid cancer xenografts, 
which confirms the data obtained for other tumors 
[6, 7]. In conclusion, the combination of Ptx with 
IR seems to be a promising modality for further pre-
clinical and clinical trials for advanced thyroid cancer.
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Fig. 2. Apoptosis induced by Ptx in tumor xenografts. Animals with advanced tumors were treated with daily i.p. Ptx injections 
at a dose of 2.5 mg/kg/day for 7 days. (a) Apoptotic cells in tumor tissue biopsies were detected at 11, 20, and 29 days, as described 
in Materials and Methods section, (x100). (b) Apoptotic index in the tumors. Data are mean ± SD. *P  < 0.01 (ANOVA)
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